Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Sponsor: Eli Lilly and Company
Summary
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
Official title: A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
750
Start Date
2024-10-21
Completion Date
2030-01
Last Updated
2026-03-13
Healthy Volunteers
No
Conditions
Interventions
LY4066434.
Administered orally.
Cetuximab
Administered intravenously.
Nab paclitaxel
Administered intravenously.
Gemcitabine
Administered intravenously.
Oxaliplatin
Administered intravenously.
Leucovorin
Administered intravenously.
Irinotecan
Administered intravenously.
5Fluorouracil
Administered intravenously.
Carboplatin
Administered intravenously.
Cisplatin
Administered intravenously.
Pemetrexed
Administered intravenously.
Pembrolizumab
Administered intravenously.
Locations (56)
University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinic
Phoenix, Arizona, United States
City of Hope
Duarte, California, United States
University of California, Los Angeles (UCLA)
Los Angeles, California, United States
University of Colorado Denver
Denver, Colorado, United States
Yale University School of Medicine - Yale Cancer Center
New Haven, Connecticut, United States
The University of Chicago Medical Center (UCMC)
Chicago, Illinois, United States
Indiana University (IU)
Indianapolis, Indiana, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Henry Ford Health System
Detriot, Michigan, United States
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Columbia University
New York, New York, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
University of Oklahoma - Health Sciences Center
Oklahoma City, Oklahoma, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Sarah Cannon Research Institute/SCRI
Nashville, Tennessee, United States
SCRI Oncology Partners
Nashville, Tennessee, United States
University of Texas Southwestern
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Swedish Cancer Institute (SCI)
Seattle, Washington, United States
Universite Libre de Bruxelles (ULB) - Institut Jules Bordet
Brussels, Belgium
Cliniques universitaires Saint-Luc
Brussels, Belgium
UZ Gent
Ghent, Belgium
Cancer Institute & Hospital, Chinese Academy of Medical Sciences
Beijing, China
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, China
Shandong Province Tumor Hospital
Jinan, China
Shanghai East Hospital, Tongji University
Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Centre Leon Berard
Lyon, France
Institut Gustave Roussy
Villejuif, France
Charite Universitaetsmedizin Berlin
Berlin, Germany
Krankenhaus Nordwest GmbH
Frankfurt, Germany
Asklepios Kliniken Hamburg GmbH - Asklepios Klinik Altona
Hamburg, Germany
SLK-Kliniken Heilbronn GmBH
Heilbronn, Germany
Universitaetsklinikum Wuerzburg
Würzburg, Germany
Centro Ricerche Cliniche di Verona s.r.l.
Verona, Italy
National Cancer Center Hospital East
Chiba, Japan
Kyoto University Hospital
Kyoto, Japan
Shizuoka Cancer Center
Shizuoka, Japan
National Cancer Center Hospital
Tokyo, Japan
Cancer Institute Hospital of JFCR
Tokyo, Japan
Hospital del Mar
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Institut Catala d'Oncologia - L'Hospitalet
Barcelona, Spain
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Regional Universitario de Malaga
Málaga, Spain
National Taiwan University Hospital Hsin-Chu Branch
Hsinchu, Taiwan
National Taiwan University Hospital
Taipei, Taiwan